FutuRx
VC Fund
Ness Ziona, Israel
FutuRx is a VC fund in Ness Ziona focused on Biotechnology and Biopharma. FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries FutuRx invests in
Stages FutuRx invests in
Countries FutuRx invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 9 (90%)
- Biopharma 5 (50%)
- Therapeutics 5 (50%)
- Life Science 4 (40%)
- Pharmaceutical 2 (20%)
Stage
- Seed 9 (90%)
- Venture - Series Unknown 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
KINNERET SAVITSKY
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Skip Therapeutics
|
Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeuticsprovide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations. | Seed / May 01, 2021 | |
A2i Therapeutics
|
A2i Therapeutics develops novel therapeutic modulators of the protein that helps to control the immune response and neurological disorders. | Seed / Dec 18, 2020 | |
Selene Therapeutics
|
Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by the regulation of the neuronal activity set point by a reduction of the neuronal mean firing rate (MFR).Selene aims to develop small molecule inhibitors of Dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme located on the inner mitochondrialmembrane and participating in several key cellular homeostatic processes. | Seed / Oct 01, 2020 | |
Circuit-Bio
|
Circuit-Bio is a synthetic biology company developing a unique platform of logical gene circuits for cancer immunotherapy. The platform used by the company focuses on creating gene circuits that can precisely and locally manufacture a combination of several immune-stimulating proteins (immunomodulators) that are only expressed in specific tumorcells. The circuit turns cancer cells into "Trojan horses" that are used as anti-tumor resources and incite a potent, long-lasting immune response. | Seed / Sep 01, 2020 | |
JAMM Therapeutics
|
JAMM Therapeutics is a drug discovery company developing small molecule modulators for the treatment of systemic lupus erythematosus (SLE).A family of cytokines known as type I IFNs exhibits antiviral, antiproliferative, and immunomodulatory functions. All type I IFNs function by attaching to the same receptor complex, which has the IFNAR1 andIFNAR2 subunits. IFNAR1 polyubiquitination, which instructs the internalized receptor for destruction in the lysosome, is one of the mechanisms regulating type I IFN activation. IFNAR1's K63-conjugated polyubiquitin chain can be disassembled by the cytoplasmic complex DUB, also known as BRISC (BRCC36 isopeptidase complex), which stabilizes IFNAR1 and encourages IFN-dependent reactions. Both in humans and mice, type I IFNs play a key role in the pathogenesis of SLE. When SLE is produced in BRISC-deficient mice, the mice show improved clinical functioning, reduced IFN responses, and protection against immunopathology linked to IFN. | Seed / May 01, 2020 | |
Protekt Therapeutics
|
ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019. | $4.1M / Venture - Series Unknown / Nov 12, 2019 | |
GliXogen Therapeutics
|
GliXogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders. All currently available approved medications for MS patients target the immune system and modulate it in a variety of ways, but they are unable to address the neurological damage that existed prior to the diagnosis.The progression of 75% of relapsing-remitting MS patients to the secondary progressive, more severe form of the disease is at least partially attributed to demyelination. | Seed / Jan 14, 2019 | |
MOYA Bio
|
MOYA Bio is developing novel E1 inhibitors for solid and hematological malignancies. The company's unique drugs are designed to target and selectively modify the Ubiquitin and Ubiquitin-Like (UBL) pathways, resulting in direct anti-tumor actions while also enhancing the effectiveness of other therapeutic methods. | Seed / Jan 01, 2019 | |
Bsense Bio Therapeutics
|
Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety. | $405K / Seed / Oct 01, 2018 | |
Ramino Bio
|
Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around. | Seed / Sep 01, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does FutuRx invest in?
FutuRx invests primarily in Biotechnology, Biopharma and Therapeutics startups, most often at Seed and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact FutuRx?
Public channels for FutuRx include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at FutuRx?
The team at FutuRx includes KINNERET SAVITSKY (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
